Nearly a decade after The Medicines Co. (MDCO) began to enroll patients in the first phase III trial of cangrelor, the antiplatelet therapy gained FDA approval late Monday to prevent blood clots in patients undergoing percutaneous coronary intervention or angioplasty, provided they were not previously treated with a P2Y12 inhibitor or receiving a glycoprotein IIb/IIIa inhibitor.